MET: A critical player in tumorigenesis and therapeutic target

Cold Spring Harbor Perspectives in Biology

Volumn 5, Issue 7, 2013, Pages

  Graveel, Carrie R ^a   Tolbert, David ^a   Vande Woude, George F ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; CARCINOGENESIS; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE; MUTATION; NEOPLASM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOGENESIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 84879761446     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a009209     Document Type: Article

References (131)

1. Abella JV, Peschard P, Naujokas MA, Lin T, Saucier C, Urbe S, Park M. 2005. Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol Cell Biol 25: 9632-9645.
2. Abounader R, Laterra J. 2005. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 7: 436-451.
3. Abounader R, Ranganathan S, Lal B, Fielding K, Book A, Dietz H, Burger P, Laterra J. 1999. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst 91: 1548-1556.
4. Aebersold DM, Landt O, Berthou S, Gruber G, Beer KT, Greiner RH, Zimmer Y. 2003. Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx. Oncogene 22: 8519-8523.
5. Apte U, Zeng G, Muller P, Tan X, Micsenyi A, Cieply B, Dai C, Liu Y, Kaestner KH, Monga SP. 2006. Activation of Wnt/b-catenin pathway during hepatocyte growth factor-induced hepatomegaly in mice. Hepatology 44: 992-1002.
6. Bardella C, Costa B, Maggiora P, Patane S, Olivero M, Ranzani GN, De Bortoli M, Comoglio PM, Di Renzo MF. 2004. Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res 64: 5154-5161.
7. Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B, Stalder D, Gruber G, Liang C, Howlett AR, et al. 2004. TheMet kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 23: 5387-5393.
8. Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E, Giordano S, Corso S, Rolland-Valognes G, Lockhart BP, et al. 2009. Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci Signal 2: er11.
9. Birchmeier W, Brinkmann V, Niemann C, Meiners S, DiCesare S, Naundorf H, Sachs M. 1997. Role of HGF/SF and c-Met in morphogenesis and metastasis of epithelial cells. Ciba Found Symp 212: 230-240.
10. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. 2003. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925.
11. Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. 1995. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376: 768-771.
12. Blume-Jensen P, Hunter T. 2001. Oncogenic kinase signalling. Nature 411: 355-365.
13. Boccaccio C, Ando M, Tamagnone L, Bardelli A, Michieli P, Battistini C, Comoglio PM. 1998. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391: 285-288.
14. Borowiak M, Garratt AN, Wustefeld T, Strehle M, Trautwein C, Birchmeier C. 2004. Met provides essential signals for liver regeneration. Proc Natl Acad Sci 101: 10608-10613.
15. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA. 1991. Identification of the hepatocyte growth factor receptor as the c-met protooncogene product. Science 251: 802-804.
16. Bussolino F, DiRenzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM. 1992. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119: 629-641.
17. Camp ER, Liu W, Fan F, Yang A, Somcio R, Ellis LM. 2005. RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann Surg Oncol 12: 273-281.
18. Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, Wang LM, Vande Woude GF. 2001. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci 98: 7443-7448.
19. Carafoli F, Chirgadze DY, Blundell TL, Gherardi E. 2005. Crystal structure of the β-chain of human hepatocyte growth factor-like/macrophage stimulating protein. FEBS J 272: 5799-5807.
20. Chirgadze DY, Hepple JP, Zhou H, Byrd RA, Blundell TL, Gherardi E. 1999. Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding. Nat Struct Biol 6: 72-79.
21. Chmielowiec J, Borowiak M, Morkel M, Stradal T, Munz B, Werner S, Wehland J, Birchmeier C, Birchmeier W. 2007. c-Met is essential for wound healing in the skin. J Cell Biol 177: 151-162.
22. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, et al. 2003. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63: 7345-7355.
23. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, Vande Woude GF. 1984. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311: 29-33.
24. Corso S, Comoglio PM, Giordano S. 2005. Cancer therapy: Can the challenge be MET? TrendsMol Med 11: 284-292.
25. Corso S, Ghiso E, Cepero V, Sierra JR, Migliore C, Bertotti A, Trusolino L, Comoglio PM, Giordano S. 2010. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer 9: 121.
26. Date K, Matsumoto K, Shimura H, Tanaka M, Nakamura T. 1997. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 420: 1-6.
27. Deakin JA, Lyon M. 1999a. Differential regulation of hepatocyte growth factor/scatter factor by cell surface proteoglycans and free glycosaminoglycan chains. J Cell Sci 112: 1999-2009.
28. Deakin JA, Lyon M. 1999b. Differential regulation of hepatocyte growth factor/scatter factor by cell surface proteoglycans and free glycosaminoglycan chains. J Cell Sci 112: 1999-2009.
29. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, Valente G, Giordano S, Cortesina G, Comoglio PM. 2000. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19: 1547-1555.
30. Donate LE, Gherardi E, Srinivasan N, Sowdhamini R, Aparicio S, Blundell TL. 1994. Molecular evolution and domain structure of plasminogen-related growth factors (HGF/SF and HGF1/MSP). Protein Sci 3: 2378-2394.
31. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
32. Fan S, Gao M, Meng Q, Laterra JJ, Symons MH, Coniglio S, Pestell RG, Goldberg ID, Rosen EM. 2005. Role of NF-kB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene 24: 1749-1766.
33. Furge KA, Zhang YW, Vande Woude GF. 2000. Met receptor tyrosine kinase: Enhanced signaling through adapter proteins. Oncogene 19: 5582-5589.
34. Gallego MI, Bierie B, Hennighausen L. 2003. Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways. Oncogene 22: 8498-8508.
35. Gao CF, Xie Q, Zhang YW, Su Y, Roys C, Zhao P, Cao B, Burgess T, Coxon A, Vande Woude G. 2006. Therapeutic potential of neutralizing antibodies to HGF/SF against human c-MET driven human tumors. In American Association for Cancer Research Annual Meeting, p. LB229. Washington, DC.
36. Gherardi E, Sandin S, Petoukhov MV, Finch J, Youles ME, Ofverstedt LG, Miguel RN, Blundell TL, Vande Woude GF, Skoglund U, et al. 2006. Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc Natl Acad Sci 103: 4046-4051.
37. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. 2012. Targeting MET in cancer: Rationale and progress. Nat Rev Cancer 12: 89-103.
38. Gonzatti-Haces M, Seth A, Park M, Copeland T, Oroszlan S, Vande Woude GF. 1988. Characterization of the TPRMET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. Proc Natl Acad Sci 85: 21-25.
39. Gordon MS, Kluger HM, Shapiro G, Kurzrock R, Edelman G, Samuel TA, Moussa AH, Ramies DA, Laird AD, Schimmoller F, et al. 2012. Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol Abstr 30: 8531.
40. Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickloff BJ, Kinsella JL, Polverini P, Rosen EM. 1993. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci 90: 1937-1941.
41. Graveel C, Su Y, Koeman J, Wang LM, Tessarollo L, Fiscella M, Birchmeier C, Swiatek P, Bronson R, Vande Woude G. 2004. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci 101: 17198-17203.
42. Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, Snider J, Davies SR, Swiatek PJ, Cottingham S, et al. 2009. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci 106: 12909-12914.
43. Gu H, Maeda H, Moon JJ, Lord JD, Yoakim M, Nelson BH, Neel BG. 2000. New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt pathway. Mol Cell Biol 20: 7109-7120.
44. Hellerstedt BA, Edelman G, Vogelzang NJ, Kluger HM, Yasenchak CA, Shen X, Ramies DA, Gordon MS. 2012. Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol Abstr 30: 7514.
45. Holmes O, Pillozzi S, Deakin JA, Carafoli F, Kemp L, Butler PJ, Lyon M, Gherardi E. 2007. Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains. J Mol Biol 367: 395-408.
46. Huh CG, Factor VM, Sanchez A, Uchida K, Conner EA, Thorgeirsson SS. 2004. Hepatocyte growth factor/cmet signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci 101: 4477-4482.
47. Itoh M, Yoshida Y, Nishida K, Narimatsu M, Hibi M, Hirano T. 2000. Role of Gab1 in heart, placenta, and skin development and growth factor-and cytokine-induced extracellular signal-regulated kinase mitogen-activated protein kinase activation. Mol Cell Biol 20: 3695-3704.
48. Jeffers M, Rong S, Vande Woude GF. 1996. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-Met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 16: 1115-1125.
49. Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, Zbar B, Vande Woude GF. 1997. Activating mutations for theMet tyrosine kinase receptor in human cancer. Proc Natl Acad Sci 94: 11445-11450.
50. Jeffers M, Fiscella M, Webb CP, Anver M, Koochekpour S, Vande Woude GF. 1998. The mutationally activated Met receptor mediates motility and metastasis. ProcNatl Acad Sci 95: 14417-14422.
51. Kirchhofer D, Yao X, Peek M, Eigenbrot C, Lipari MT, Billeci KL, Maun HR, Moran P, Santell L, Wiesmann C, et al. 2004. Structural and functional basis of the serine protease-like hepatocyte growth factor β-chain in Met binding and signaling. J Biol Chem 279: 39915-39924.
52. Knudsen BS, Vande Woude G. 2008. Showering c-Met dependent cancers with drugs. Curr Opin Genet Dev 18: 87-96.
53. Kong-Beltran M, Stamos J, Wickramasinghe D. 2004. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 6: 75-84.
54. Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N, Holcomb T, Pujara K, Stinson J, Fu L, et al. 2006. Somatic mutations lead to an oncogenic deletion of Met in lung cancer. Cancer Res 66: 283-289.
55. Lamorte L, Rodrigues S, Naujokas M, Park M. 2002a. Crk synergizes with epidermal growth factor for epithelial invasion and morphogenesis and is required for the Met morphogenic program. J Biol Chem 277: 37904-37911.
56. Lamorte L, Royal I, Naujokas M, Park M. 2002b. Crk adapter proteins promote an epithelial-mesenchymallike transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions. Mol Biol Cell 13: 1449-1461.
57. Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, Schmidt L, Zbar B, Vande Woude GF. 2000. A novel germ line juxtamembraneMet mutation in human gastric cancer. Oncogene 19: 4947-4953.
58. Liang TJ, Reid AE, Xavier R, Cardiff RD, Wang TC. 1996. Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. J Clin Invest 97: 2872-2877.
59. Lietha D, Chirgadze DY, Mulloy B, Blundell TL, Gherardi E. 2001. Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor. EMBO J 20: 5543-5555.
60. Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG, Weiser MR. 2011. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res 17: 472-482.
61. Love CA, Harlos K, Mavaddat N, Davis SJ, Stuart DI, Jones EY, Esnouf RM. 2003. The ligand-binding face of the semaphorins revealed by the high-resolution crystal structure of SEMA4D. Nat Struct Biol 10: 843-848.
62. Lowenstein EJ, Daly RJ, Batzer AG, Li W, Margolis B, Lammers R, Ullrich A, Skolnik EY, Bar-Sagi D, Schlessinger J. 1992. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 70: 431-442.
63. Lyon M, Deakin JA, Lietha D, Gherardi E, Gallagher JT. 2004. The interactions of hepatocyte growth factor/scatter factor and its NK1 and NK2 variants with glycosaminoglycans using a modified gel mobility shift assay. Elucidation of the minimal size of binding and activatory oligosaccharides. J Biol Chem 279: 43560-43567.
64. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R. 2003. c-METmutational analysis in small cell lung cancer: Novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63: 6272-6281.
65. Maroun CR, Holgado-Madruga M, Royal I, Naujokas MA, Fournier TM, Wong AJ, Park M. 1999. The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the Met receptor tyrosine kinase. Mol Cell Biol 19: 1784-1799.
66. Maroun CR, Naujokas MA, Holgado-Madruga M, Wong AJ, Park M. 2000. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signalregulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol 20: 8513-8525.
67. Merchant M, Zhang Y, Su Y, Romero M, Louie S, Severin C, Mendoza N, Zheng Z, Dekoning T, DW K, et al. 2008. Combination efficacy with MetMAb and erlotinib in a NSCLC tumor model highlight therapeutic opportunities for c-Met inhibitors in combination with EGFR inhibitors. In Proceedings of the 99th Annual Meeting of the American Association for Cancer Research. San Diego, CA.
68. Michieli P, Basilico C, Pennacchietti S, Maffe A, Tamagnone L, Giordano S, Bardelli A, Comoglio PM. 1999. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 18: 5221-5231.
69. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, Comoglio PM. 2004. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6: 61-73.
70. Monga SP, Mars WM, Pediaditakis P, Bell A, Mule K, Bowen WC, Wang X, Zarnegar R, Michalopoulos GK. 2002. Hepatocyte growth factor induces Wnt-independent nuclear translocation of β-catenin after Met-bcatenin dissociation in hepatocytes. Cancer Res 62: 2064-2071.
71. Montesano R, Soriano JV, Malinda KM, Ponce ML, Bafico A, Kleinman HK, Bottaro DP, Aaronson SA. 1998. Differential effects of hepatocyte growth factor isoforms on epithelial and endothelial tubulogenesis. Cell Growth Differ 9: 355-365.
72. Mosesson Y, Mills GB, Yarden Y. 2008. Derailed endocytosis: An emerging feature of cancer. Nat Rev Cancer 8: 835-850.
73. Moshitch-Moshkovitz S, Tsarfaty G, Kaufman DW, Stein GY, Shichrur K, Solomon E, Sigler RH, Resau JH, Vande Woude GY, Tsarfaty I. 2006. In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met. Neoplasia 8: 353-363.
74. Muller M, Morotti A, Ponzetto C. 2002. Activation of NF-kB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol Cell Biol 22: 1060-1072.
75. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S. 1989. Molecular cloning and expression of human hepatocyte growth factor. Nature 342: 440-443.
76. Oliner KS, Tang R, Anderson A, Lan Y, Iveson T, Donehower RC, Jiang Y, Dubey S, Loh E. 2012. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol 30 (Abstr): 4005.
77. Ong SH, Dilworth S, Hauck-Schmalenberger I, Pawson T, Kiefer F. 2001. ShcA and Grb2 mediate polyoma middle T antigen-induced endothelial transformation and Gab1 tyrosine phosphorylation. EMBO J 20: 6327-6336.
78. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. 2002. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 16: 3074-3086.
79. Otsuka T, Takayama H, Sharp R, Celli G, LaRochelle WJ, Bottaro DP, Ellmore N, Vieira W, Owens JW, Anver M, et al. 1998. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res 58: 5157-5167.
80. Park M, Dean M, Cooper CS, Schmidt M, O'Brien SJ, Blair DG, Vande Woude GF. 1986. Mechanism of met oncogene activation. Cell 45: 895-904.
81. Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, Kim BJ, Bae JH, Hong YK, Lee KS, et al. 1999. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 59: 307-310.
82. Pediaditakis P, Monga SP, Mars WM, Michalopoulos GK. 2002. Differential mitogenic effects of single chain hepatocyte growth factor (HGF)/scatter factor and HGF/NK1 following cleavage by factor Xa. J Biol Chem 277: 14109-14115.
83. Peek M, Moran P, Mendoza N, Wickramasinghe D, Kirchhofer D. 2002. Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa. J Biol Chem 277: 47804-47809.
84. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. 2003. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347-361.
85. Peschard P, Park M. 2007. From Tpr-Met to Met, tumorigenesis and tubes. Oncogene 26: 1276-1285.
86. Phaneuf D, Moscioni AD, LeClair C, Raper SE, Wilson JM. 2004. Generation of a mouse expressing a conditional knockout of the hepatocyte growth factor gene: Demonstration of impaired liver regeneration. DNACell Biol 23: 592-603.
87. Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, Bull SB, Chughtai N, Germain D, Omeroglu A, et al. 2009. Met induces mammary tumors with multiple pathologies and is associated with both poor outcome and basal-type breast cancers. Proc Natl Acad Sci 106: 12903-12908.
88. Qi J, McTigue MA, Rogers A, Lifshits E, Christensen JG, Janne PA, Engelman JA. 2011. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 71: 1081-1091.
89. Reshetnikova G, Troyanovsky S, Rimm DL. 2007. Definition of a direct extracellular interaction between Met and Ecadherin. Cell Biol Int 31: 366-373.
90. Rimassa L, Porta C, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlieberghe H, Trojan J, Kolligs FT, Weiss A, et al. 2012. Tivantinib (ARQ197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT). J Clin Oncol 30 (Abstr): 4006.
91. Rodrigues SP, Fathers KE, Chan G, Zuo D, Halwani F, Meterissian S, Park M. 2005. CrkI and CrkII function as key signaling integrators for migration and invasion of cancer cells. Mol Cancer Res 3: 183-194.
92. Ronsin C, Muscatelli F, Mattei MG, Breathnach R. 1993. A novel putative receptor protein tyrosine kinase of the met family. Oncogene 8: 1195-1202.
93. Rosario M, Birchmeier W. 2003. How to make tubes: Signaling by the Met receptor tyrosine kinase. Trends Cell Biol 13: 328-335.
94. Rozakis-Adcock M, McGlade J, Mbamalu G, Pelicci G, Daly R, Li W, Batzer A, Thomas S, Brugge J, Pelicci PG, et al. 1992. Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature 360: 689-692.
95. Rubin JS, Day RM, Breckenridge D, Atabey N, Taylor WG, Stahl SJ, Wingfield PT, Kaufman JD, Schwall R, Bottaro DP. 2001. Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-Met interaction facilitates signaling. J Biol Chem 276: 32977-32983.
96. Sachs M, Brohmann H, Zechner D, Muller T, Hulsken J, Walther I, Schaeper U, Birchmeier C, Birchmeier W. 2000. Essential role of Gab1 for signaling by the c-Met receptor in vivo. J Cell Biol 150: 1375-1384.
97. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K, Christensen JG, et al. 2003. A novel small moleculeMet inhibitor induces apoptosis in cells transformed by the oncogenic TPRMET tyrosine kinase. Cancer Res 63: 5462-5469.
98. Saucier C, Khoury H, Lai KM, Peschard P, Dankort D, Naujokas MA, Holash J, Yancopoulos GD, Muller WJ, Pawson T, et al. 2004. The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. Proc Natl Acad Sci 101: 2345-2350.
99. Schaeper U, Gehring NH, Fuchs KP, Sachs M, Kempkes B, Birchmeier W. 2000. Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J Cell Biol 149: 1419-1432.
100. Schiering N, Knapp S, Marconi M, Flocco MM, Cui J, Perego R, Rusconi L, Cristiani C. 2003. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proc Natl Acad Sci 100: 12654-12659.
101. Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M, Gherardi E, Birchmeier C. 1995. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373: 699-702.
102. Schmidt L, Duh F-M, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, et al. 1997. Germline and somatic mutations in the tyrosine kinase domain of the Met proto-oncogene in papillary renal carcinomas. Nat Genet 16: 68-73.
103. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, Lubensky I, Neumann HP, Brauch H, Decker J, et al. 1999. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18: 2343-2350.
104. Schoffski P, Elisei R, Müller S, Brose MS, Shah MH, Licitra LF, Jarzab B, Medvedev V, Kreissl M, Niederle B, et al. 2012. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol Abstr 30: 5508.
105. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S, et al. 2011. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 29: 3307-3315.
106. Shattuck DL, Miller JK, Carraway KL III, Sweeney C. 2008. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 68: 1471-1477.
107. Shen Z, Yang ZF, Gao Y, Li JC, Chen HX, Liu CC, Poon RT, Fan ST, Luk JM, Sze KH, et al. 2008. The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma. Cancer Res 68: 404-414.
108. Shimomura T, Kondo J, Ochiai M, Naka D, Miyazawa K, Morimoto Y, Kitamura N. 1993. Activation of the zymogen of hepatocyte growth factor activator by thrombin. J Biol Chem 268: 22927-22932.
109. Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, Vande Woude GF. 2004. RNA interference reveals that ligand-independent Met activity is required for tumor cell signaling and survival. Cancer Res 64: 7962-7970.
110. Smith MR, Sweeney C, Rathkopf DE, Scher HI, Logothetis C, George DJ, Higano CS, Yu EY, Harzstark AL, Small EJ, et al. 2012. Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE). J Clin Oncol Abstr 30: 4513.
111. Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, Robinet G, Clement-Duchene C, Barlesi F, et al. 2011. Final efficacy results from OAM4558 g, a randomized phase II study evaluatingMetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol Abstr 29: 7505.
112. Stahl SJ, Wingfield PT, Kaufman JD, Pannell LK, Cioce V, Sakata H, Taylor WG, Rubin JS, Bottaro DP. 1997. Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced in Escherichia coli. Biochem J 326: 763-772.
113. Stamos J, Lazarus RA, Yao X, Kirchhofer D, Wiesmann C. 2004. Crystal structure of the HGF β-chain in complex with the Sema domain of the Met receptor. EMBO J 23: 2325-2335.
114. Stella GM, Benvenuti S, Gramaglia D, Scarpa A, Tomezzoli A, Cassoni P, Senetta R, Venesio T, Pozzi E, Bardelli A, et al. 2011. METmutations in cancers of unknown primary origin (CUPs). Hum Mutat 32: 44-50.
115. Stoker M, Gherardi E, Perryman M, Gray J. 1987. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327: 239-242.
116. Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, Aaronson SA, Merlino G. 1997. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci 94: 701-706.
117. Tolbert WD, Daugherty J, Gao C, Xie Q, Miranti C, Gherardi E, Woude GV, Xu HE. 2007. A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist. Proc Natl Acad Sci 104: 14592-14597.
118. Uehara Y, Minowa O, Mori C, Shiota K, Kuno J, Noda T, Kitamura N. 1995. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373: 702-705.
119. Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, et al. 2010. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12: 468-476.
120. Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM. 2001. Activation of theMet receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 153: 1023-1034.
121. Wang X, DeFrances MC, Dai Y, Pediaditakis P, Johnson C, Bell A, Michalopoulos GK, Zarnegar R. 2002. A mechanism of cell survival: Sequestration of Fas by the HGF receptor Met. Mol Cell 9: 411-421.
122. Wang X, Le P, Liang C, Chan J, Kiewlich D, Miller T, Harris D, Sun L, Rice A, Vasile S, et al. 2003. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther 2: 1085-1092.
123. Wang D, Li Z, Messing EM, Wu G. 2005. The SPRYdomaincontaining SOCS box protein 1 (SSB-1) interacts with METand enhances the hepatocyte growth factor-induced Erk-Elk-1-serum response element pathway. J Biol Chem 280: 16393-16401.
124. Weidner KM, Arakaki N, Hartmann G, Vandekerckhove J, Weingart S, Rieder H, Fonatsch C, Tsubouchi H, Hishida T, Daikuhara Y, et al. 1991. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci 88: 7001-7005.
125. Winer EP, Tolaney S, Nechushtan H, Berger R, Kurzrock R, Ron I, Schoffski P, Awada A, Yasenchak CA, Burris HA, et al. 2012. Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol Abstr 30: 535.
126. Youles M, Holmes O, Petoukhov MV, Nessen MA, Stivala S, Svergun DI, Gherardi E. 2008. Engineering the NK1 fragment of hepatocyte growth factor/scatter factor as a MET receptor antagonist. J Mol Biol 377: 616-622.
127. Zhang Y-W, Wang L-M, Jove R, Vande Woude GF. 2002. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 21: 217-226.
128. Zhang Y-W, Su Y, Volpert OV, Vande Woude GF. 2003. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin-1 regulation. Proc Natl Acad Sci 100: 12718-12723.
129. Zhang YW, Su Y, Lanning N, Gustafson M, Shinomiya N, Zhao P, Cao B, Tsarfaty G, Wang LM, Hay R, et al. 2005. Enhanced growth of humanMet-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 24: 101-106.
130. Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, et al. 2010. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res 70: 6880-6890.
131. Zou C, Ma J, Wang X, Guo L, Zhu Z, Stoops J, Eaker AE, Johnson CJ, Strom S, Michalopoulos GK, et al. 2007. Lack of Fas antagonism by Met in human fatty liver disease. Nat Med 13: 1078-1085.